Tempest Therapeutics, Inc. (TPST) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Tempest Therapeutics, Inc. (TPST) closed at USD 0.63 on 2026-10-14, a change of -94.2 % over the past year, with a market capitalization of USD 10.73M.

Tempest Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Tempest Therapeutics, Inc. key figures

Previous close

USD 0.63 (2026-10-14)

1-year change

-94.2 %

Market cap

USD 10.73M

Enterprise value

USD 16.93M

P/E ratio (trailing)

-0.17

P/E ratio (forward)

-0.53

EPS (trailing)

-3.66

EPS (forward)

-1.21

PEG ratio

n/a

Price to book

-9.34

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.09

Employees

4

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Tempest Therapeutics, Inc. and compare it with other stocks.